Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1

American Journal of Physiology - Renal Physiology

Volumn 300, Issue 5, 2011, Pages 1180-1192

  Wu, Qing Qing ^a   Wang, Yanxia ^a   Senitko, Martin ^a   Meyer, Colin ^a   Wigley, W Christian ^a   Ferguson, Deborah A ^a   Grossman, Eric ^a   Chen, Jianlin ^a   Zhou, Xin J ^b   Hartono, John ^a   Winterberg, Pamela ^b   Chen, Bo ^d   Agarwal, Anapam ^d   Lu, Christopher Y ^a,c  

^a Departments of Internal Medicine   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Acute kidney injury; Cisplatin; Heme oxygenase 1; Ischemia

Indexed keywords

BARDOXOLONE METHYL; CD31 ANTIGEN; HEME OXYGENASE 1; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRANSCRIPTION FACTOR NRF2;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; IMMUNOFLUORESCENCE; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY ISCHEMIA; KIDNEY TUBULE CELL; LEUKOCYTE; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPERFUSION INJURY;

EID: 79955763790     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00353.2010     Document Type: Article

References (72)

1. Ahmad R, Raina D, Meyer C, Kharbanda S, Kufe D. Triterpenoid CDDO-Me blocks the NF-kappa B pathway by direct inhibition of IKKbeta on Cys-179. J Biol Chem 281: 35764-35769, 2006.
2. Alam J, Cook JL. How many transcription factors does it take to turn on the heme oxygenase-1 gene? Am J Respir Cell Mol Biol 36: 166-174, 2007.
3. Aleksunes LM, Goedken MJ, Rockwell CE, Thomale J, Manautou JE, Klaassen CD. Transcriptional regulation of renal cytoprotective genes by Nrf2 and its potential use as a therapeutic target to mitigate cisplatininduced nephrotoxicity. J Pharmacol Exp Ther 335: 2-12, 2010.
4. Alvarez-Maqueda M, El Bekay R, Alba G, Monteseirin J, Chacon P, Vega A, Martin-Nieto J, Bedoya FJ, Pintado E, Sobrino F. 15-Deoxydelta 12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes. J Biol Chem 279: 21929-21937, 2004.
5. Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma- modulating activity. Hypertension 43: 993-1002, 2004.
6. Boulanger H, Mansouri R, Gautier JF, Glotz D. Are peroxisome proliferator-activated receptors new therapeutic targets in diabetic and non-diabetic nephropathies? Nephrol Dial Transplant 21: 2696-2702, 2006.
7. Brady HR, Clarkson MR, Lieberthal W, Brenner BM, Rector F. Acute renal failure. In: The Kidney. St. Louis, MO: Saunders, 2004, p.1215-1270.
8. Brezis M, Rosen S, Silva P, Epstein FH. Renal ischemia: a new perspective. Kidney Int 26: 375-383, 1984.
9. Chatterjee PK, Patel NS, Cuzzocrea S, Brown PA, Stewart KN, Mota-Filipe H, Britti D, Eberhardt W, Pfeilschifter J, Thiemermann C. The cyclopentenone prostaglandin 15-deoxy-Delta(12,14)-prostaglandin J2 ameliorates ischemic acute renal failure. Cardiovasc Res 61: 630-643, 2004.
10. Chertow GM, Soroko SH, Paganini EP, Cho KC, Himmelfarb J, Ikizler TA, Mehta RL. Mortality after acute renal failure: models for prognostic stratification and risk adjustment. Kidney Int 70: 1120-1126, 2006.
11. Fledderus JO, Boon RA, Volger OL, Hurttila H, Yla-Herttuala S, Pannekoek H, Levonen AL, Horrevoets AJ. KLF2 primes the antioxidant transcription factor Nrf2 for activation in endothelial cells. Arterioscler Thromb Vasc Biol 28: 1339-1346, 2008.
12. Gong P, Stewart D, Hu B, Li N, Cook J, Nel A, Alam J. Activation of the mouse heme oxygenase-1 gene by 15-deoxy-Delta(12,14)-prostaglandin J2 is mediated by the stress response elements and transcription factor Nrf2. Antioxid Redox Signal 4: 249-257, 2002.
13. Gozzelino R, Jeney V, Soares MP. Mechanisms of cell protection by heme oxygenase-1. Annu Rev Pharmacol Toxicol 50: 323-354, 2010.
14. Haller H, Dragun D, Miethke A, Park JK, Weis A, Lippoldt A, Gross V, Lust FC. Antisense oligonucleotides for ICAM 1 attenuate reperfusion injury and renal failure in the rat. Kidney Int 50: 473-480, 1996.
15. Hirayama A, Nagase S. Electron paramagnetic resonance imaging of oxidative stress in renal disease. Nephron Clin Pract 103: c71-e76, 2006.
16. Hong C, Tontonoz P. Coordination of inflammation and metabolism by PPAR and LXR nuclear receptors. Curr Opin Genet Dev 18: 461-467, 2008.
17. Hsu CY, Ordonez JD, Chertow GM, Fan D, McCulloch CE, Go AS. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74: 101-107, 2008.
18. Iglesias P, Diez JJ. Peroxisome proliferator-activated receptor gamma agonists in renal disease. Eur J Endocrinol 154: 613-621, 2006.
19. Jarmi T, Agarwal A. Heme oxygenase and renal disease. Curr Hypertens Rep 11: 56-62, 2009.
20. Ji Y, Lee HJ, Goodman C, Uskokovic M, Liby K, Sporn M, Suh N. The synthetic triterpenoid CDDO-imidazolide induces monocytic differentiation by activating the Smad and ERK signaling pathways in HL60 leukemia cells. Mol Cancer Ther 5: 1452-1458, 2006.
21. Kanjanabuch T, Ma LJ, Chen J, Pozzi A, Guan Y, Mundel P, Fogo AB. PPAR-gamma agonist protects podocytes from injury. Kidney Int 71: 1232-1239, 2007.
22. Kashgarian M. Acute tubular necrosis an ischemic renal injury. In: Heptinstall's Pathology of the Kidney (5th ed.), edited by Jennette JC, Olsen JC, Schwartz MM, and Silva FG. Philadelphia, PA: Lippincott- Raven, 1999, p. 863-889.
23. Kelly KJ, Sandoval RM, Dunn KW, Molitoris BA, Dagher PC. A novel method to determine specificity and sensitivity of the TUNEL reaction in the quantitation of apoptosis. Am J Physiol Cell Physiol 284: C1309-C1318, 2003.
24. Kelly KJ, Williams WW Jr, Colvin RB, Bonventre JV. Antibody to intercellular adhesion molecule 1 protects the kidney against ischemic injury. Proc Natl Acad Sci USA 91: 812-816, 1995.
25. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-ramos JC, Bonventre JV. Intercellular adhesion molecule-1- deficient mice are protected against ischemic renal injury. J Clin Invest 97: 1056-1063, 1996.
26. Khosla N, Soroko SB, Chertow GM, Himmelfarb J, Ikizler TA, Paganini E, Mehta RL. Preexisting chronic kidney disease: a potential for improved outcomes from acute kidney injury. Clin J Am Soc Nephrol 4: 1914-1919, 2009.
27. Kiew LV, Munavvar AS, Law CH, Azizan AN, Nazarina AR, Sidik K, Johns EJ. Effect of antisense oligodeoxynucleotides for ICAM-1 on renal ischaemia-reperfusion injury in the anaesthetised rat. J Physiol 557: 981-989, 2004.
28. Kim EH, Na HK, Surh YJ. Upregulation of VEGF by 15-deoxy- Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. Ann NY Acad Sci 1090: 375-384, 2006.
29. Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ, Bochkov VN, Exner M, Binder BR, Leitinger N. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator- activated receptors. Arterioscler Thromb Vasc Biol 27: 1276-1282, 2007.
30. Lee JM, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA. Nrf2, a multi-organ protector? FASEB J 19: 1061-1066, 2005.
31. Leonard MO, Kieran NE, Howell K, Burne MJ, Varadarajan R, Dhakshinamoorthy S, Porter AG, O'Farrelly C, Rabb H, Taylor CT. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J 20: 2624-2626, 2006.
32. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 275: 1489-1494, 1996.
33. Liby K, Voong N, Williams CR, Risingsong R, Royce DB, Honda T, Gribble GW, Sporn MB, Letterio JJ. The synthetic triterpenoid CDDOImidazolide suppresses STAT phosphorylation and induces apoptosis in myeloma and lung cancer cells. Clin Cancer Res 12: 4288-4293, 2006.
34. Liby KT, Yore MM, Sporn MB. Triterpenoids and rexinoids as multifunctional agents for the prevention and treatment of cancer. Nat Rev Cancer 7: 357-369, 2007.
35. Lieberthal W, Nigam SK, Bonventre JV, Brezis M, Siegel N, Rosen S, Portilla D, Venkatachalam M. Acute renal failure. I. Relative importance of proximal vs. distal tubular injury. Am J Physiol Renal Physiol 275: F623-F631, 1998.
36. Lin TN, Cheung WM, Wu JS, Chen JJ, Lin H, Liou JY, Shyue SK, Wu KK. 15d-Prostaglandin J2 protects brain from ischemia-reperfusion injury. Arterioscler Thromb Vasc Biol 26: 481-487, 2006.
37. Ling X, Konopleva M, Zeng Z, Ruvolo V, Stephens LC, Schober W, McQueen T, Dietrich M, Madden TL, Andreeff M. The novel triterpenoid C-28 methyl ester of 2-cyano-3, 12-dioxoolen-1, 9-dien-28-oic acid inhibits metastatic murine breast tumor growth through inactivation of STAT3 signaling. Cancer Res 67: 4210-4218, 2007.
38. Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP, Rabb H. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int 76: 277-285, 2009.
39. Lo L, Liu KD, Hsu CY. Long-term outcomes after acute kidney injury: where we stand and how we can move forward. Am J Kidney Dis 53: 928-931, 2009.
40. Lucke B. Lower nephron nephrosis. Mil Surg 99: 371-396, 1946.
41. Morse D, Lin L, Choi AM, Ryter SW. Heme oxygenase-1, a critical arbitrator of cell death pathways in lung injury and disease. Free Radic Biol Med 47: 1-12, 2009.
42. Nath KA. Heme oxygenase-1: a provenance for cytoprotective pathways in the kidney and other tissues. Kidney Int 70: 432-443, 2006.
43. Nath KA, Norby SM. Reactive oxygen species and acute renal failure. Am J Med 109: 665-678, 2000.
44. Nguyen T, Nioi P, Pickett CB. The Nrf2-antioxidant response element signaling pathway and its activation by oxidative stress. J Biol Chem 284: 13291-13295, 2009.
45. Okada M, Yan SF, Pinsky DJ. Peroxisome proliferator-activated receptor- gamma (PPAR-gamma) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J 16: 1861-1868, 2002.
46. Oliver J, Mac DM, Tracy A. The pathogenesis of acute renal failure associated with traumatic and toxic injury; renal ischemia, nephrotoxic damage and the ischemic episode. J Clin Invest 30: 1307-1439, 1951.
47. Padanilam BJ. Cell death induced by acute renal injury: a perspective on the contributions of apoptosis and necrosis. Am J Physiol Renal Physiol 284: F608-F627, 2003.
48. Park MK, Kim CH, Kim YM, Kang YJ, Kim HJ, Seo HG, Lee JH, Chang KC. Akt-dependent heme oxygenase-1 induction by NS-398 in C6 glial cells: a potential role for CO in prevention of oxidative damage from hypoxia. Neuropharmacology 53: 542-551, 2007.
49. Rabb H, Mendiola CC, Dietz J, Saba SR, Issekutz TB, Abanilla F, Bonventre JV, Ramirez G. Role of CD11a and CD11b in ischemic acute renal failure in rats. Am J Physiol Renal Fluid Electrolyte Physiol 267: F1052-F1058, 1994.
50. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: an assessment from bench to bedside. Kidney Int 70: 1223-1233, 2006.
51. Sato N, Moore FA, Kone BC, Zou L, Smith MA, Childs MA, Moore-Olufemi S, Schultz SG, Kozar RA. Differential induction of PPAR-γ by luminal glutamine and iNOS by luminal arginine in the rodent postische-mic small bowel. Am J Physiol Gastrointest Liver Physiol 290: G616-G623, 2006.
52. Sikorski EM, Hock T, Hill-Kapturczak N, Agarwal A. The story so far: molecular regulation of the heme oxygenase-1 gene in renal injury. Am J Physiol Renal Physiol 286: F425-F441, 2004.
53. Sivarajah A, Chatterjee PK, Patel NS, Todorovic Z, Hattori Y, Brown PA, Stewart KN, Mota-Filipe H, Cuzzocrea S, Thiemermann C. Agonists of peroxisome-proliferator activated receptor-gamma reduce renal ischemia/reperfusion injury. Am J Nephrol 23: 267-276, 2003.
54. Soares MP, Marguti I, Cunha A, Larsen R. Immunoregulatory effects of HO-1: how does it work? Curr Opin Pharmacol 9: 482-489, 2009.
55. Solez K. Pathogenesis of acute renal failure. Int Rev Exp Pathol 24: 277-333, 1983.
56. Sporn MB, Liby K, Yore MM, Suh N, Albini A, Honda T, Sundararajan C, Gribble GW. Platforms and networks in triterpenoid pharmacology. Drug Dev Res 68: 174-182, 2007.
57. Suh N, Roberts AB, Birkey Reffey S, Miyazono K, Itoh S, ten Dijke P, Heiss EH, Place AE, Risingsong R, Williams CR, Honda T, Gribble GW, Sporn MB. Synthetic triterpenoids enhance transforming growth factor beta/Smad signaling. Cancer Res 63: 1371-1376, 2003.
58. Thurman JM, Ljubanovic D, Edelstein CL, Gilkeson GS, Holers VM. Lack of a functional alternative complement pathway ameliorates ischemic acute renal failure in mice. J Immunol 170: 1517-1523, 2003.
59. Vaidya VS, Ozer JS, Dieterle F, Collings FB, Ramirez V, Troth S, Muniappa N, Thudium D, Gerhold D, Holder DJ, Bobadilla NA, Marrer E, Perentes E, Cordier A, Vonderscher J, Maurer G, Goering PL, Sistare FD, Bonventre JV. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 28: 478-485, 2010.
60. Venkatachalam MA, Griffin KA, Lan R, Geng H, Saikumar P, Bidani AK. Acute kidney injury: a springboard for progression in chronic kidney disease. Am J Physiol Renal Physiol 298: F1078-F1094, 2010.
61. Villacorta L, Schopfer FJ, Zhang J, Freeman BA, Chen YE. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. Clin Sci (Lond) 116: 205-218, 2009.
62. Wayman NS, Hattori Y, McDonald MC, Mota-Filipe H, Cuzzocrea S, Pisano B, Chatterjee PK, Thiemermann C. Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size. FASEB J 16: 1027-1040, 2002.
63. Wright MM, Kim J, Hock TD, Leitinger N, Freeman BA, Agarwal A. Human heme oxygenase-1 induction by nitro-linoleic acid is mediated by cyclic AMP, AP-1, and E-box response element interactions. Biochem J422: 353-361, 2009.
64. Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes. Mol Cancer Ther 6: 154-162, 2007.
65. Yates MS, Tran QT, Dolan PM, Osburn WO, Shin S, McCulloch CC, Silkworth JB, Taguchi K, Yamamoto M, Williams CR, Liby KT, Sporn MB, Sutter TR, Kensler TW. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice. Carcinogenesis 30: 1024-1031, 2009.
66. Ympa YP, Sakr Y, Reinhart K, Vincent JL. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 118: 827-832, 2005.
67. Yoon HY, Kang NI, Lee HK, Jang KY, Park JW, Park BH. Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme. Biochem Pharmacol 75: 2214-2223, 2008.
68. Yore MM, Liby KT, Honda T, Gribble GW, Sporn MB. The synthetic triterpenoid 1-[2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oyl]imidazole blocks nuclear factor-kappaB activation through direct inhibition of IkappaB kinase beta. Mol Cancer Ther 5: 3232-3239, 2006.
69. Yoshimura R, Matsuyama M, Segawa Y, Tsuchida K, Takemoto Y, Kuratsukuri K, Kawahito Y, Shinka T, Sano H, Nakatani T. Study of peroxisome proliferator-activated receptor (PPAR)-gamma in renal ischemia- reperfusion injury. Transplant Proc 36: 1946-1948, 2004.
70. Yu X, Shao XG, Sun H, Li YN, Yang J, Deng YC, Huang YG. Activation of cerebral peroxisome proliferator-activated receptors gamma exerts neuroprotection by inhibiting oxidative stress following pilocarpine- induced status epilepticus. Brain Res 1200: 146-158, 2008.
71. Yuen PS, Jo SK, Holly MK, Hu X, Star RA. Ischemic and nephrotoxic acute renal failure are distinguished by their broad transcriptomic responses. Physiol Genomics 25: 375-386, 2006.
72. Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. Biochim Biophys Acta 1771: 915-925, 2007.